Genome-wide association study identifies ephrin type a receptors implicated in paclitaxel induced peripheral sensory neuropathy

Journal of Medical Genetics

Volumn 50, Issue 9, 2013, Pages 599-605

  Leandro García, Luis J ^a   Inglada Pérez, Lucía ^a,b   Pita, Guillermo ^a   Hjerpe, Elisabet ^c   Leskelä, Susanna ^a   Jara, Carlos ^d   Mielgo, Xabier ^d   González Neira, Anna ^a   Robledo, Mercedes ^a,b   Åvall Lundqvist, Elisabeth ^c   Gréen, Henrik ^e,f,g   Rodríguez Antona, Cristina ^a,b  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^e LINKÖPING UNIVERSITY   (Sweden)

^f ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^g DEPARTMENT OF FORENSIC GENETICS AND FORENSIC TOXICOLOGY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; EPHRIN RECEPTOR A4; EPHRIN RECEPTOR A5; EPHRIN RECEPTOR A6; LIM PROTEIN; LIMK2 PROTEIN; PACLITAXEL; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CAUCASIAN; DRUG DOSE REDUCTION; DRUG SAFETY; FEMALE; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC RISK; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS (TOPIC); MULTIPLE CYCLE TREATMENT; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SENSORY NEUROPATHY; SINGLE NUCLEOTIDE POLYMORPHISM;

GENETICS; GENOME-WIDE; MOLECULAR GENETICS; ONCOLOGY; PERIPHERAL NERVE DISEASE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASMS; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, EPH FAMILY;

EID: 84883172515     PISSN: 00222593     EISSN: 14686244     Source Type: Journal    
DOI: 10.1136/jmedgenet-2012-101466     Document Type: Article

References (40)

1. Mielke S, Sparreboom A, Mross K. Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. Eur J Cancer 2006;42:24-30.
2. Argyriou AA, Koltzenburg M, Polychronopoulos P, Papapetropoulos S, Kalofonos HP. Peripheral nerve damage associated with administration of taxanes in patients with cancer. Crit Rev Oncol Hematol 2008;66:218-28.
3. Shemesh OA, Spira ME. Paclitaxel induces axonal microtubules polar reconfiguration and impaired organelle transport: implications for the pathogenesis of paclitaxel-induced polyneuropathy. Acta Neuropathol 2010;119:235-48.
4. Green H, Soderkvist P, Rosenberg P, Horvath G, Peterson C. mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin Cancer Res 2006;12(3 Pt 1):854-9.
5. Hasmats J, Kupershmidt I, Rodriguez-Antona C, Su QJ, Khan MS, Jara C, Mielgo X, Lundeberg J, Green H. Identification of candidate SNPs for drug induced toxicity from differentially expressed genes in associated tissues. Gene 2012;506:62-8.
6. Leandro-Garcia LJ, Leskela S, Jara C, Green H, Avall-Lundqvist E, Wheeler HE, Dolan ME, Inglada-Perez L, Maliszewska A, de Cubas AA, Comino-Mendez I, Mancikova V, Cascon A, Robledo M, Rodriguez-Antona C. Regulatory polymorphisms in beta-tubulin IIa are associated with paclitaxel-induced peripheral neuropathy. Clin Cancer Res 2012;18:4441-8.
7. Leskela S, Jara C, Leandro-Garcia LJ, Martinez A, Garcia-Donas J, Hernando S, Hurtado A, Vicario JC, Montero-Conde C, Landa I, Lopez-Jimenez E, Cascon A, Milne RL, Robledo M, Rodriguez-Antona C. Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity. Pharmacogenomics J 2011;11:121-9.
8. Sissung TM, Mross K, Steinberg SM, Behringer D, Figg WD, Sparreboom A, Mielke S. Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur J Cancer 2006;42:2893-6.
9. Baldwin RM, Owzar K, Zembutsu H, Chhibber A, Kubo M, Jiang C, Watson D, Eclov RJ, Mefford J, McLeod HL, Friedman PN, Hudis CA, Winer EP, Jorgenson EM, Witte JS, Shulman LN, Nakamura Y, Ratain MJ, Kroetz DL. A genome-wide association study identifies novel loci for paclitaxel-induced peripheral neuropathy in CALGB 40101. Clinical Cancer Research 2012;18:5099-109.
10. Green H, Khan MS, Jakobsen-Falk I, Avall-Lundqvist E, Peterson C. Impact of CYP3A5*3 and CYP2C8-HapC on paclitaxel/carboplatin-induced myelosuppression in patients with ovarian cancer. J Pharm Sci 2011;100:4205-9.
11. Green H, Soderkvist P, Rosenberg P, Mirghani RA, Rymark P, Lundqvist EA, Peterson C. Pharmacogenetic studies of paclitaxel in the treatment of ovarian cancer. Basic Clin Pharmacol Toxicol 2009;104:130-7.
12. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, Adeyemo A, Cooper R, Ward R, Lander ES, Daly MJ, Altshuler D. The structure of haplotype blocks in the human genome. Science 2002;296:2225-9.
13. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007;447:661-78.
14. Barrette B, Calvo E, Vallieres N, Lacroix S. Transcriptional profiling of the injured sciatic nerve of mice carrying the Wld(S) mutant gene: identification of genes involved in neuroprotection, neuroinflammation, and nerve regeneration. Brain Behav Immun 2010;24:1254-67.
15. Goldshmit Y, Galea MP, Wise G, Bartlett PF, Turnley AM. Axonal regeneration and lack of astrocytic gliosis in EphA4-deficient mice. J Neurosci 2004;24:10064-73.
16. Goldshmit Y, Spanevello MD, Tajouri S, Li L, Rogers F, Pearse M, Galea M, Bartlett PF, Boyd AW, Turnley AM. EphA4 blockers promote axonal regeneration and functional recovery following spinal cord injury in mice. PLoS One 2011;6: e24636.
17. Munro KM, Perreau VM, Turnley AM. Differential gene expression in the EphA4 knockout spinal cord and analysis of the inflammatory response following spinal cord injury. PLoS One 2012;7:e37635.
18. Van Hoecke A, Schoonaert L, Lemmens R, Timmers M, Staats KA, Laird AS, Peeters E, Philips T, Goris A, Dubois B, Andersen PM, Al-Chalabi A, Thijs V, Turnley AM, van Vught PW, Veldink JH, Hardiman O, Van Den Bosch L, Gonzalez-Perez P, Van Damme P, Brown RH Jr., van den Berg LH, Robberecht W. EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. Nat Med 2012;18:1418-22.
19. Hertz DL, Motsinger-Reif AA, Drobish A, Winham SJ, McLeod HL, Carey LA, Dees EC. CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast Cancer Res Treat 2012;134:401-10.
20. Miao H, Wang B. EphA receptor signaling-complexity and emerging themes. Semin Cell Dev Biol 2012;23:16-25.
21. Akaneya Y, Sohya K, Kitamura A, Kimura F, Washburn C, Zhou R, Ninan I, Tsumoto T, Ziff EB. Ephrin-A5 and EphA5 interaction induces synaptogenesis during early hippocampal development. PLoS One 2010;5:e12486.
22. Parmentier-Batteur S, Finger EN, Krishnan R, Rajapakse HA, Sanders JM, Kandpal G, Zhu H, Moore KP, Regan CP, Sharma S, Hess JF, Williams TM, Reynolds IJ, Vacca JP, Mark RJ, Nantermet PG. Attenuation of scratch-induced reactive astrogliosis by novel EphA4 kinase inhibitors. J Neurochem 2011;118:1016-31.
23. Savelieva KV, Rajan I, Baker KB, Vogel P, Jarman W, Allen M, Lanthorn TH. Learning and memory impairment in Eph receptor A6 knockout mice. Neurosci Lett 2008;438:205-9.
24. Park S, Frisen J, Barbacid M. Aberrant axonal projections in mice lacking EphA8 (Eek) tyrosine protein kinase receptors. EMBO J 1997;16:3106-14.
25. Lantieri F, Glessner JT, Hakonarson H, Elia J, Devoto M. Analysis of GWAS top hits in ADHD suggests association to two polymorphisms located in genes expressed in the cerebellum. Am J Med Genet B Neuropsychiatr Genet 2010;153B:1127-33.
26. Fijal BA, Stauffer VL, Kinon BJ, Conley RR, Hoffmann VP, Witte MM, Zhao F, Houston JP. Analysis of gene variants previously associated with iloperidone response in patients with schizophrenia who are treated with risperidone. J Clin Psychiatry 2012;73:367-71.
27. Lavedan C, Licamele L, Volpi S, Hamilton J, Heaton C, Mack K, Lannan R, Thompson A, Wolfgang CD, Polymeropoulos MH. Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study. Mol Psychiatry 2009;14:804-19.
28. Meng Y, Takahashi H, Meng J, Zhang Y, Lu G, Asrar S, Nakamura T, Jia Z. Regulation of ADF/cofilin phosphorylation and synaptic function by LIM-kinase. Neuropharmacology 2004;47:746-54.
29. Endo M, Ohashi K, Mizuno K. LIM kinase and slingshot are critical for neurite extension. J Biol Chem 2007;282:13692-702.
30. Po'uha ST, Shum MS, Goebel A, Bernard O, Kavallaris M. LIM-kinase 2, a regulator of actin dynamics, is involved in mitotic spindle integrity and sensitivity to microtubule-destabilizing drugs. Oncogene 2010;29:597-607.
31. Gui C, Miao Y, Thompson L, Wahlgren B, Mock M, Stieger B, Hagenbuch B. Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol 2008;584:57-65.
32. de Graan AJ, Lancaster CS, Obaidat A, Hagenbuch B, Elens L, Friberg LE, de Bruijn P, Hu S, Gibson AA, Bruun GH, Corydon TJ, Mikkelsen T, Walker AL, Du G, Loos WJ, van Schaik RH, Baker SD, Mathijssen RH, Sparreboom A. Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. Clin Cancer Res 2012;18:4433-40.
33. Cleeland CS, Farrar JT, Hausheer FH. Assessment of cancer-related neuropathy and neuropathic pain. Oncologist 2010;15(Suppl 2):13-18.
34. International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002;360:505-15.
35. Gutierrez-Gutierrez G, Sereno M, Miralles A, Casado-Saenz E, Gutierrez-Rivas E. Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies. Clin Transl Oncol 2010;12:81-91.
36. Jaggi AS, Singh N. Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy. Toxicology 2012;291:1-9.
37. Makowsky R, Pajewski NM, Klimentidis YC, Vazquez AI, Duarte CW, Allison DB, de los Campos G. Beyond missing heritability: prediction of complex traits. PLoS Genet 2011;7:e1002051.
38. Wheeler HE, Gamazon ER, Wing C, Njiaju UO, Njoku C, Baldwin RM, Owzar K, Jiang C, Watson D, Shterev I, Kubo M, Zembutsu H, Winer EP, Hudis CA, Shulman LN, Nakamura Y, Ratain MJ, Kroetz DL, Cox NJ, Dolan ME. Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of paclitaxel-induced sensory peripheral neuropathy. Clin Cancer Res 2013;19:491-9.
39. Yang J, Benyamin B, McEvoy BP, Gordon S, Henders AK, Nyholt DR, Madden PA, Heath AC, Martin NG, Montgomery GW, Goddard ME, Visscher PM. Common SNPs explain a large proportion of the heritability for human height. Nat Genet 2010;42:565-9.
40. Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, Boehnke M, Abecasis GR, Willer CJ. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics 2010;26:2336-7.